ACannabis is back in 2022. With the theme, ‘Bridging the gap: evidence, confidence, access‘, ACannabis will be held over two jam packed days, Tuesday 15th March to Wednesday 16th March, and is the one location to stay up to date with all facets of the medicinal cannabis industry. Due to the ever changing landscape, ACannabis 2022 will be a virtual conference and exhibition with a wide range of networking opportunities available. It will be immersive, engaging and deliver an:
Please join us for the inaugural MCIA networking event to socialise, celebrate and contribute ideas for developing future networking events! Each occasion will include a speaker and presentation on a topic of interest to the industry.
Developed by MTPConnect in partnership with Deloitte Access Economics, MCIA was pleased to initiate consultation with MTPConnect to develop this evidence based report for the industry and we thank MTPConnect for their support and work in developing this resource.
Medicinal Cannabis Industry Australia (MCIA) is pleased to partner with FreshLeaf for the third year running in the release of FreshLeaf’s latest comprehensive analysis of medicinal cannabis products, pricing and patients.
MCIA is excited to invite you to an exclusive webinar hosted by FreshLeaf Analytics and AJD Media to present the H2 2021 FreshLeaf Analytics Market Report.
This report will be the 7th major publication from FreshLeaf, who has been covering the Australian medical cannabis industry since 2017, and is the leading source of information, data and insight on the sector.
Registration is now open for the TGA ‘Meeting Your Obligations – Supplying medicinal cannabis in Australia’ Workshop. MCIA has worked with TGA to deliver this workshop to assist members and others in the industry understand their obligations and specifically assist to understand the requirements for S3 over-the-counter (OTC) product registration requirements.
Medicinal Cannabis Industry Australia (MCIA) welcomes the Therapeutic Goods Administration (TGA) announcement of its final decision regarding down-scheduling of low-dose CBD, including the significant change to the maximum dose which has been increased to 150mg/day.
MCIA had recommended changes to the interim decision, and in particular the low daily dose, to ensure that there is an effective pathway for S3 CBD products. A report commissioned by MCIA supported a higher dose based on safety and efficacy, and hence, ability to meet the evidentiary requirements for the proposed registration pathway. MCIA is pleased that TGA’s further consideration of this information, along with other public submissions, and the advice of the Joint Committee of the Advisory Committees for Medicines Scheduling and Chemicals Scheduling at its November 2020 meeting, has led to a lifting of the daily dose.
In launching ACannabis we noted that the medicinal cannabis industry is rapidly evolving, with many voices in the conversation. ACannabis is about harnessing the collective talent, knowledge and expertise that is critical to seize the opportunities in this exciting new industry which is providing an important new medicine for patients.
Medicinal Cannabis Industry Australia (MCIA) is delighted to welcome Dr Richard Di Natale as the inaugural chair of the newly established Medicinal Cannabis Health Advisory Council.
“Richard has been a great champion of medicinal cannabis access for patients and will provide invaluable guidance as chair of this unique and important Advisory Council” said Peter Crock Chair of MCIA.
In responding to the Therapeutic Goods Administration’s (TGA) interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines at appropriate dosage levels, Medicinal Cannabis Industry Australia (MCIA) has recommended further change to the proposed scheduling to ensure that there is an effective pathway for S3 CBD products.
Medicinal cannabis has an important role to play in improving health outcomes. MCIA supports down- scheduling of CBD to S3, which has the potential to provide patients with improved access to a safe low dose cannabis product for medical use.